CS Diagnostics Corp. Reports $204,000 Revenue and $71,219 Net Income for Fiscal Year 2025

CS Diagnostics Corp. reported total revenue of $204,000 for the fiscal year ending December 31, 2025, a significant increase from $110,911 in 2024 and approximately $126,040 in 2023. This growth was primarily driven by a related-party Affiliate Revenue Agreement (ARA), which provided fixed monthly contributions of $17,000. The company recorded a net income of $71,219 for 2025, a notable rise from a net income of $761 in 2024 and a net loss of approximately $22,000 in 2023. However, the revenue generated from the ARA does not reflect core business operations and may not be sustainable in the future.

Operating expenses for CS Diagnostics increased to $132,781 in 2025 from $110,150 in the previous year, attributed mainly to higher general and administrative costs related to corporate activities and regulatory compliance. The company’s total assets as of December 31, 2025, were reported at $499,485,555, with intangible assets making up the majority of this figure. Current assets also saw an increase to $85,555, primarily due to higher cash balances, although the cash on hand was limited at $6,813, raising concerns about the company's liquidity.

The company has not yet generated revenue from product sales and does not have a measurable market share in the medical device and oncology support market, which is characterized by significant regulatory requirements and competition from established players. CS Diagnostics is focused on obtaining necessary regulatory approvals and pursuing commercialization of its product candidates, including its flagship product, CS Protect-Hydrogel. The company is also exploring strategic partnerships to enhance its market presence.

Management has acknowledged that the company’s liquidity remains constrained, with cash flow from operations being negative despite reporting net income. The reliance on the ARA for revenue introduces uncertainty, as the agreement can be terminated with short notice. Future performance will depend on the company’s ability to secure additional financing, achieve market acceptance, and generate revenue from product-based activities. The company plans to address its liquidity challenges through equity financings and strategic partnerships, although there is no assurance that such financing will be available on acceptable terms.

In terms of governance, CS Diagnostics has faced challenges with its internal controls, specifically regarding the accuracy of financial reporting. Management has identified a material weakness in its internal control processes and is actively working on remediation efforts. The company’s future outlook remains uncertain, as it must navigate regulatory hurdles and market conditions while striving to establish a sustainable revenue stream.